> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ventyx’s Oral NLRP3 Inhibitor Shows Promise in Study
- URL: https://www.fdaweb.com/ventyxs-oral-nlrp3-inhibitor-shows-promise-in-study/
- Published: 2025-10-23T12:00:00.000Z
- Updated: 2026-09-14T15:24:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160094

Ventyx Biosciences is reporting positive Phase 2 data for its oral NLRP3 inhibitor VTX3232 in patients with obesity and cardiovascular risk factors. The 175-participant study examined VTX3232 versus placebo, alone or in combination with semaglutide (Novo Nordisk's Ozempic and Wegovy), and evaluated safety and tolerability as the primary endpoint, and effects on inflammation (measured by high-sensitivity C-reactive protein or hsCRP) as the secondary endpoint. The company says data showed that VTX3232 was associated with large and rapid reductions in key inflammatory markers associated with cardiovascular risk, though the therapy did not affect weight loss even when combined with semaglutide.

Ventyx says that in the study, VTX3232 monotherapy cut hsCRP levels by 78% at week 12, compared to a 3% increase for placebo. It says about 70% of treated patients reached target hsCRP levels below 2 mg/L — a threshold considered indicative of lower residual inflammatory risk. The drug also drove statistically significant reductions in interleukin-6 to a median of 1.6 ng/L, below the 1.65 ng/L cardiovascular risk threshold, as well as in other inflammatory biomarkers including lipoprotein(a), fibrinogen and erythrocyte sedimentation rate, it says.

The Phase 2 study found no safety concerns, with rates of adverse events comparable to placebo, according to the company. Grade 3 or higher adverse events occurred in about 2–5% of participants across treatment groups.